Efficacy and Tolerability of Olanzapine in Elderly Patients with Psychotic Disorders: A Prospective Study

References

• Jeste DV, Caligiuri MP, Paulsen JS, et al.: Risk of tardive dyskinesia in older patients; a prospective longitudinal study of 266 outpatients. Arch Gen Psychiatry 1995; 52: 756–765
   Google Scholar
• Salz BL, Kane JM, Woerner MG, et at. Prospective study of tardive dyskinesia in the elderly. Psychopharmocol Bull 1989; 25:52–56
   PubMedGoogle Scholar
• Avorn J, Manane M, Everitt DE, et aL: Clinical assessments of extrapyramidal signs in nursing home patients given anti-psychotic medications. Arch Intern Med 1994; 154:1113–1117
   Google Scholar
• Bymaster FP. In vitro and in vivo biochemistry of olanzapine. J Clin Psychiatry Monograph 1997; 15(2):10–12
   Google Scholar
• Baldwin DS, Montgomery SA: First clinical experience with olanzapine (LY170053): Results of an open-label and safety and dose-ranging study in patients with schizophrenia. Int Clin Psychopharmacol 1995; 10:239–244
   PubMed Web of Science ®Google Scholar
• Tollefson GD, Beasley CM, Tran PV, et aL: Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffec-five disorders: Results of an international collaborative. Am J Psychiatry 1997; 154:4
   Google Scholar
• Beasley CM, Efficacy of olanzapine: An overview of pivotal clinical trials. J Clin Psychiatry Monograph 1997; 15(2):16–18
   Google Scholar
• Kay SR, Fiszbein A, Opler LA. The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophrenia Bull 1987; 13:261–276
   Google Scholar
• Guy W, ed.: ECDEU Assessment Manual for Psychopharma-cology. Publication ADM 76–338. Washington DC: U.S. De-partment of Health, Education and Welfare; 1976
   Google Scholar
• Addington D, Addington J, Schissel BA: Calgary Depression Scale for Schizophrenia: Depression rating scale for schizo-phrenics. Schizophrenia Res 1990; 3:247–251
   PubMed Web of Science ®Google Scholar
• Folstein MF, Folstein SE, Hugh PR: Mini Mental State. A practical method for grading the cognitive state for the clini-cians. J Psychiat Res 1975; 12:189–198
   Google Scholar
• Chouinard G, Ross-Chounard A, Annable L, Jones BD: Ex-trapyramidal Symptoms Rating. Am J Neurol Sci 1980; 7:233
   Google Scholar
• Blin 0, Azorin JM, Bouhours P. Antipsychotic and amdolytic properties of risperidone, haloperidol and methotrimeprazine in schizophrenic patients. J Clin Psychopharmacol 1996; 16(1):38–44
   Google Scholar
• Kopala LC, Good KP, Honer WG. Extrapyramidal symptoms in first-episode schizophrenia: Response to low-dose risperi-done. J Clin Psychopharmacol 1997; 17(4):308–313
   Google Scholar
• Nair NP. Therapeutic equivalence of risperidone given once daily and twice daily in patients with schizophrenia. J Clin Psychopharmacol 1998; 18(2):103–110
   Google Scholar
• Tollefson GD. Olanzapine: A new antipsychotic agent. J Clin Psychiatry Monograph 1997; 15(3):19–24
   Google Scholar
• Madhusoodanan S, Suresh P, Brenner R, et al.: Experience with the atypical antipsychotics—risperidone and olanzapine in the elderly. Ann Clin Psychiatry 1999; II(3):113–118
   Google Scholar
• Sajatovic M, Perez D, Brescan D, et aL: Olanzapine therapy in elderly patients with schizophrenia. psychopharmacol bull; in press.
   Google Scholar
• Sweet RA, Pollack BG: New atypical anti psychotics: Experi-ence and utility in the elderly, Drugs Aging 1998; 12:115–127
   Google Scholar
• Satterlee WG, Reams SG, Bums PR, et al.: A clinical update on olanzapine treatment in schizophrenia and in elderly Alz-heimer's disease patients, Psychopharmacol Bull 1995; 31:534
   Google Scholar
• Moss AJ, Robinson JL: Long QT syndrome. Heart Disease Stroke 1992,1:309
   Google Scholar
• Bourne KF, Zipes DP, Heger JJ, et al.: The influence of autonomic nervous system on the QT interval in man. Am J. Cardiol 1982,50:1099
   Google Scholar
• Moore NA: Behavioral pharmacology of olanzapine. J Clin Psychiatry Monograph 1997; 15(2):13–15
   Google Scholar